Menu
close
Please contact us for more information or to learn if you are eligible to participate.
This is a nonrandomized, single arm feasibility study with the primary goal of evaluating the safety profile of the combination of atezolizumab and bevacizumab in patients with advanced/metastatic HCC with Child-Pugh B7 and B8 liver disease who have received no prior systemic therapy.
Principal Investigator | Dr. Lee C. Drinkard |
Co-PI | Edgar Lopez Pacheco |
Sponsor | Kristen Spencer, DO, MPH Rutgers Cancer Institute of New Jersey |
Type of Trial | Interventional |